Athenex (ATNXQ) Form 4 Athenex / Song-Yi Zhang ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Zhang Song-Yi

(Last) (First) (Middle)

C/O ATHENEX, INC.

1001 MAIN STREET, SUITE 600

(Street)

BUFFALO NY 14203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Athenex, Inc. [ ATNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/23/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/23/2018		S		25,748	D	$17.28(1)	5,163,134	I(2)(3)	By Mandra Medical Limited(2)(3)
Common Stock								4,000	D
Common Stock								181,818	I(3)(4)	By iBase Ltd.(3)(4)
Common Stock								678,880	I(3)(5)	By Avalon Biomedical (Management) Limited(3)(5)
Common Stock								287,176	I(2)(3)	By Mandra Health Limited(2)(3)
Common Stock								107,181	I(3)(5)(6)	By Avalon Polytom (HK) Limited(3)(5)(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.5							05/18/2016(7)	05/18/2025	Common Stock	80,000		80,000	D
Stock Option (Right to Buy)	$9							10/17/2017(8)	10/17/2025	Common Stock	48,000		48,000	D
Stock Option (Right to Buy)	$11							(9)	06/13/2027	Common Stock	28,500		28,500	D
Stock Option (Right to Buy)	$9							(10)	07/17/2025	Common Stock	54,904		54,904	I(3)(5)	By Avalon Biomedical (Management) Limited(3)(5)

1. Name and Address of Reporting Person^*

Zhang Song-Yi

(Last) (First) (Middle)

C/O ATHENEX, INC.

1001 MAIN STREET, SUITE 600

(Street)

BUFFALO NY 14203

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Mandra Medical Ltd

(Last) (First) (Middle)

NEWHAVEN TRUSTEES (BVI) LTD., 3RD FLOOR

J&C BUILDING, P.O. BOX 933, ROAD TOWN

(Street)

TORTOLA D8 VG1110

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Beansprouts Ltd

(Last) (First) (Middle)

NEWHAVEN TRUSTEES (BVI) LTD., 3RD FLOOR

J&C BUILDING, P.O. BOX 933, ROAD TOWN

(Street)

TORTOLA D8 VG1110

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Mui Bing How Tammy

(Last) (First) (Middle)

C/O ATHENEX, INC., 1001 MAIN STREET

SUITE 600

(Street)

BUFFALO NY 14203

(City) (State) (Zip)

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $17.25 to $17.54. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected.

2. Each of Mandra Health Limited and Mandra Medical Limited are wholly-owned subsidiaries of Beansprouts Limited. Song-Yi Zhang ("Mr. Zhang") is a member of the board of directors of each of Mandra Health Limited and Mandra Medical Limited and, together with his spouse, owns all of the outstanding interests in Beansprouts Limited and shares voting and dispositive power over the shares held by it.

3. Mr. Zhang disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Zhang is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

4. Mr. Zhang is the sole owner and director of iBase Ltd. and has sole voting and dispositive power over the shares held by iBase Ltd.

5. Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect, wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mr. Zhang, together with his spouse, indirectly owns all of the outstanding interests in Mandra Medical Limited, which owns 10.82% of the outstanding interests in Avalon Global, and Mr. Zhang serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.

6. These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.

7. The option vested in full on May 18, 2016.

8. The option vested in full on October 17, 2017.

9. The option vests in four equal annual installments beginning on June 13, 2018.

10. The option vests in three equal annual installments beginning on July 17, 2016.

Remarks:

	Song-Yi Zhang, By: /s/ Teresa Bair, Attorney-in-Fact	08/27/2018
	Mandra Medical Limited, By: Song-Yi Zhang, Director, By: /s/ Teresa Bair, Attorney-in-Fact	08/27/2018
	Beansprouts Limited, By: Song-Yi Zhang, Director, By: /s/ Teresa Bair, Attorney-in-Fact	08/27/2018
	Mui Bing How Tammy, By: /s/ Teresa Bair, Attorney-in-Fact	08/27/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.